Commensalism

Ring Therapeutics Presents New Data on Anellogy™ Platform at the 27th Annual American Society of Gene & Cell Therapy Conference

Retrieved on: 
화요일, 5월 7, 2024
Commensalism, AMD, Flagship Pioneering, Tropism, MD, Cell, AAV, Eye, Potential, Real-time, Human, DNA, Patient, Gene, Immune system, ANV, MBA, NHP, Therapy, Vaccine

CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize genetic medicines with its commensal virome platform, today announced new preclinical data demonstrating successful transduction and redosability of its Anellovector within non-human primates, as well as expanded payload capacity for the vector beyond the natural genome size of anelloviruses (ANV). The data, which will be presented as one oral presentation and two posters at the 27th Annual America Society of Gene & Cell Therapy (ASGCT) conference, showcases the viability of Anellovectors as the next generation of viral vectors.

Key Points: 
  • The data, which will be presented as one oral presentation and two posters at the 27th Annual America Society of Gene & Cell Therapy (ASGCT) conference, showcases the viability of Anellovectors as the next generation of viral vectors.
  • Additionally, the expanded payload capacity of Anellovectors widens the therapeutic potential of this novel vector class allowing even more patients to be potentially treated.
  • Unlike AAV, which appears to exhibit a strict packaging limit, Anellovectors allow for the packaging of genomes larger than the wild-type genome.
  • A combination of qPCR and next-generation sequencing was used to verify that the encapsidated expanded cargo DNA is intact, circular, and single-stranded.

Ring Therapeutics Raises $86.5 Million in Series C Funding to Create Next Generation Programmable Medicines

Retrieved on: 
목요일, 3월 9, 2023
Investment, Ring, RNA, Flagship Pioneering, Therapy, General partnership, DNA, Patient, Commensalism, Virus, MBA, Entrepreneurship, MD, Escape Room, Human, CMO, Vaccine, Pharmaceutical industry, INVU (album)

CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today announced that it raised $86.5 million in Series C funding, bringing its total funds raised to date to $230 million. Investors included Alexandria Venture Investments; Altitude Life Science Ventures; CJ Investment; Ring’s founder, Flagship Pioneering; Invus; Kyowa Kirin Co., Ltd; Partners Investment; funds and accounts advised by T. Rowe Price Associates, Inc.; UPMC Enterprises, and others including all of Ring’s existing institutional shareholders.

Key Points: 
  • “This raise underlines our goal to progress the potentially transformative therapeutics from our Anellogy platform towards the patients that need them,” said Tuyen Ong, MD, MBA, Chief Executive Officer at Ring and CEO-Partner at Flagship Pioneering.
  • Ring has developed the world’s first and only platform, the Anellogy™ platform, to discover and harness the unique characteristics of these viruses as programmable medicines capable of delivering a wide array of payloads including DNA and RNA in a highly-tropic, redosable manner.
  • Through its Anellogy™ platform, Ring has developed the largest anellovirus database to date, having sequenced and identified over 5,000 anelloviruses from human samples.
  • Ring has already begun harnessing this expansive diversity which offers tremendous optionality with respect to tissue- and cellular-level tropism, vectorization, in vitro assembly and paradigm-shifting manufacturing modularity.

Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022

Retrieved on: 
목요일, 10월 13, 2022
Infection, Private Securities Litigation Reform Act, Food and Drug Administration Amendments Act of 2007, Susceptibility, NASDAQ, CDI, Pharmacist, Nasdaq, Treatment, Next Stage with You, Society of Infectious Diseases Pharmacists, Journal, Commensalism, Infectious Diseases Society of America, Vancomycin, Safety, Poster, Quality of life, Randomness, SMMT, Knowledge, Company, Marketing, Summit, PIDS, GLOBE, Clinical trial, The Journal of Infectious Diseases, Ridinilazole, Research, Security (finance), Giovanni, Trial of the century, U.S. Securities and Exchange Commission, IDSA, Diarrhea, Risk, Clostridioides difficile (bacteria), Patient, Clostridioides difficile infection, Coronavirus, Food, Efficacy, Society, Recurrence, COVID-19, Epidemiology, Pharmaceutical industry, Vaccine, Medical device, Clostridium, Clostridioides, DRS

Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) and its product candidate, ridinilazole, will have an oral podium presentation and a poster presentation at IDWeek 2022.

Key Points: 
  • Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) and its product candidate, ridinilazole, will have an oral podium presentation and a poster presentation at IDWeek 2022.
  • In the Ri-CoDIFy study, ridinilazole resulted in a meaningful reduction in the rate of recurrence of C. diff.
  • infection (8.1% vs 17.3%) and achieved a numerically higher sustained clinical response1 rate (73.0% vs 70.7%) than vancomycin.
  • We are pleased to inform that the results of our clinical study validated the assertions of Drs.

Arrakis Therapeutics Appoints James Mutamba, PhD, as Chief Business Officer

Retrieved on: 
월요일, 12월 6, 2021
Oncology, Health, Technology, Nanotechnology, Genetics, Pharmaceutical, Biotechnology, Patient, Harvard University, PureTech Health, Judgement, MIT, Biological engineering, Arrakis Therapeutics, BS, Exosome, RSM, Biology, Commensalism, Cancer, Pfizer, Doctor of Philosophy, University, Business, University of North Carolina, Corporation, MIT Sloan School of Management, Nasdaq, Twitter, Research, Chemistry, RNA, Therapy, LinkedIn, Multimedia, Translation, Department, Growth, Pharmaceutical industry, Management

Arrakis Therapeutics , a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that James Mutamba, PhD, has joined the company as Chief Business Officer.

Key Points: 
  • Arrakis Therapeutics , a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that James Mutamba, PhD, has joined the company as Chief Business Officer.
  • View the full release here: https://www.businesswire.com/news/home/20211206005128/en/
    Arrakis Chief Business Officer James Mutamba PhD (Photo: Business Wire)
    We are delighted to welcome James to the Arrakis leadership team.
  • He brings exceptional expertise and judgment in business development, strategy and capital formation that will help Arrakis realize the tremendous opportunities enabled by our proprietary platform, said Michael Gilman, PhD, Chief Executive Officer of Arrakis.
  • Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA.

GRO Biosciences Strengthens Management Team With Appointment of Veteran Biotechnology Executive, Edward Stewart as Chief Business Officer

Retrieved on: 
화요일, 11월 16, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, Lists of diseases, Cornell University, Therapy, Commercial, Ribon, Entrepreneurship, CEO, MBA, Immune system, Doctor of Philosophy, Harvard Medical School, SVP, George Church, CBO, Instagram, Facebook, NSAA, Commensalism, Twitter, Merrimack Pharmaceuticals, Biotechnology, Company, LinkedIn, Business development, Patient, FDA, Pharmaceutical industry

GRO Biosciences Inc. (GRObio), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the hiring of veteran industry executive, Edward Tad Stewart , who joins the team as Chief Business Officer (CBO).

Key Points: 
  • GRO Biosciences Inc. (GRObio), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the hiring of veteran industry executive, Edward Tad Stewart , who joins the team as Chief Business Officer (CBO).
  • Mr. Stewart has worked extensively in business and corporate development in the biotechnology and pharmaceutical space for more than 20 years.
  • He has played an integral strategic role in scaling platform biotechnology companies from early stages through FDA-approval and product launch.
  • Mr. Stewart served most recently as Chief Business Officer of Ribon Therapeutics.

Holobiome Wins USD1 Million in Research Funding from CSB to Advance Microbiome Solutions for Pain

Retrieved on: 
목요일, 10월 28, 2021
Science, Depression, Neuropathic pain, Research, Peripheral neuropathy, Quality of life, Bacteria, Disease, Atlas, Brain, NEU, Commensalism, CEO, Iida, Inflammation, Alzheimer's disease, Inflammatory bowel disease, Pain, Health, Gut microbiota, Therapy, Data analysis, Doctor of Philosophy, Mouse, Scientific Reports, Tumor microenvironment, Pharmaceutical industry, Antibiotics, Gum arabic

The project sponsorship follows Corundum Systems Biology's June 2021 seed stage capital investment in Holobiome.

Key Points: 
  • The project sponsorship follows Corundum Systems Biology's June 2021 seed stage capital investment in Holobiome.
  • Holobiome was established in 2018 to advance human microbiome science beyond academia, with a particular focus on the relationship between the human gut and the brain.
  • Recent research by Holobiome and by its scientific advisors has implicated microbial influences on modulating neurotransmission along the gut-brain-axis.1,2,3
    "Recent evidence suggests the microbiome plays a role in regulating pain sensitivity and the inflammatory response," says Holobiome's CEO Dr. Philip Strandwitz.
  • "The future of microbiome therapeutics will be precision, and this project will drive that future," Dr. Strandwitz says.